Get the Stockscreener App
2.13
3.62%
-0.08
After Hours:
2.14
0.01
+0.47%
Alx Oncology Holdings Inc stock is traded at $2.13, with a volume of 647.37K.
It is down -3.62% in the last 24 hours and down -8.97% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$2.21
Open:
$2.21
24h Volume:
647.37K
Relative Volume:
1.23
Market Cap:
$279.45M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.7172
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
+0.47%
1M Performance:
-8.97%
6M Performance:
+95.41%
1Y Performance:
+100.94%
1-Day Range:
$2.01
$2.26
1-Week Range:
$2.01
$2.3583
52-Week Range:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.13 | 289.95M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
ALX 2025 10-K: Net loss $101.7M, EPS $(1.90); operating loss $(104.0)M - TradingView
Aug Momentum: What is ALX Oncology Holdings Incs book value per share2026 AllTime Highs & Low Risk High Win Rate Picks - baoquankhu1.vn
Alx Oncology Earnings Call Highlights Biomarker Momentum - TipRanks
ALX Oncology initiated with a Buy at UBS - Yahoo Finance
Aug Retail: Does ALX Oncology Holdings Inc stock have upside surprise potentialWatch List & Consistent Income Trade Ideas - baoquankhu1.vn
ALX Oncology (NASDAQ:ALXO) Coverage Initiated by Analysts at UBS Group - MarketBeat
QURE Stock Crashes 32% in a Week: Here's What You Should Know - Finviz
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - Yahoo Finance
Mirum Completes Enrollment & Screening in Liver Disease Studies - TradingView
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update - MarketBeat
Pharma News: Can Piedmont Office Realty Trust Inc grow without external fundingStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - marketscreener.com
ALXO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO) - Seeking Alpha
Earnings Scheduled For February 27, 2026 - Sahm
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q4 2025 Earnings Call Transcript - Insider Monkey
ALXO's Progress in Clinical Trials and Financial Strength - GuruFocus
ALX Oncology (NASDAQ:ALXO) Posts Earnings Results - MarketBeat
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... By GuruFocus - Investing.com Canada
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... - Yahoo Finance
ALX Oncology Q4 2025 Earnings Call Transcript - MarketBeat
ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology (ALXO) Q4 2025 Earnings Transcript - AOL.com
Earnings call transcript: ALX Oncology Q4 2025 misses EPS forecast, stock dips - Investing.com Canada
ALX Oncology Q4 Earnings Call Highlights - MarketBeat
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal data ahead - TradingView
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal trial readiness - TradingView
ALXO Prepares for Key Clinical Milestones with Evorpacept and AL - GuruFocus
ALX ONCOLOGY ($ALXO) Releases Q4 2025 Earnings - Quiver Quantitative
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
ALX Oncology (NASDAQ: ALXO) raises $150M and extends cash runway to 2028 - Stock Titan
ALXO: Clinical advances and cost controls drive improved financials and extended cash runway - TradingView
ALXO SEC FilingsAlx Oncology Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look Ahead: ALX Oncology Holdings's Earnings Forecast - Benzinga
ALX Oncology (ALXO) Projected to Post Quarterly Earnings on Friday - Defense World
ALX Oncology Holdings (ALXO) Price Target Increased by 11.11% to 3.40 - Nasdaq
Is Teva Pharmaceutical Industries (TEVA) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology Holdings Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Will ALX Oncology Holdings Inc stock recover after earnings2025 Support & Resistance & Verified Short-Term Plans - baoquankhu1.vn
ALXO Should I Buy - Intellectia AI
EV Market: Is ALX Oncology Holdings Inc a stock for growth or value investorsEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
ALX Oncology (ALXO) Expected to Announce Earnings on Friday - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Is ALX Oncology Holdings Inc. stock dividend yield sustainable2025 Historical Comparison & Fast Entry and Exit Trade Plans - mfd.ru
ALX Oncology Pursues Multiple Near-Term Catalysts For Two Novel Cancer Treatments - RTTNews
Tax-driven stock sale by ALX Oncology (ALXO) CAO Shelly Pinto - Stock Titan
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 - Investing News Network
Analyst Upgrade: Does ALX Oncology Holdings Inc stock have upside surprise potential2025 Market Sentiment & Growth Oriented Trade Recommendations - baoquankhu1.vn
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):